Cell Metabolism:林建谍团队发现脂肪细胞可产生一种抑制肝癌的激素

2022-08-17 王聪 “生物世界”公众号

非酒精性脂肪肝开始是肝脏中相对良性的脂肪堆积,但这种疾病会发展为非酒精性脂肪性肝炎(NASH),还会增加患肝癌的风险。

非酒精性脂肪肝开始是肝脏中相对良性的脂肪堆积,但这种疾病会发展为非酒精性脂肪性肝炎(NASH),还会增加患肝癌的风险。

2022年8月15日,密歇根大学医学中心林建谍教授团队在 Cell 子刊 Cell Metabolism 上发表了题为:Neuregulin 4 suppresses NASH-HCC development by restraining tumor-prone liver microenvironment 的研究论文。

该研究发现,脂肪细胞分泌的一种激素NRG4能够抑制NASH向肝癌的发展,而且还可以作为NASH相关肝癌的治疗靶点,这一发现为开发针对肝细胞癌(肝癌的最主要类型)的疗法提供了新方向。

肝脏包含许多不同类型的细胞,包括各种免疫细胞。此前,林建谍团队使用使用单细胞RNA测序技术构建了一个肝细胞图谱,以及健康和NASH小鼠肝脏细胞间信号转导蓝图。

林建谍教授表示,NASH引起的肝癌和病毒性肝炎引起的肝癌并不相同,前者通常在没有肝硬化的情况下发展,这表明NASH相关的肝癌可能有着不同的疾病机制。

在这项发表在 Cell Metabolism 上的最新研究中,研究团队希望确定NASH状态中的特定分子变化,这些变化会破坏肝脏中各种细胞类型间的平衡和相互作用,从而找到潜在的治疗靶点来逆转NASH向肝癌的进展。

研究团队观察到在患有NASH的小鼠模型中,T细胞和巨噬细胞这两种免疫细胞出现变化,T细胞显示出功能障碍特征,而巨噬细胞出现了癌症相关分子特征,这些变化可能有助于肝细胞癌的发展。

林建谍教授表示,研究团队在T细胞和巨噬细胞中观察到的变化类似于肿瘤微环境,而且这些变化在出现明显的癌症特征前就已发生,这也提示了我们,或许这些肝脏微环境的变化可以为肝癌细胞的出现和生长提供“肥沃的土壤”,它们看起来就像正常的肝脏,一旦发展为NASH,就会帮助癌细胞茁壮成长。

林建谍教授团队此前发现,一种主要由脂肪细胞分泌的激素——NRG4(神经调节蛋白4),可以保护小鼠的肝脏免受NASH侵害,NRG4激素的减少或丧失会导致更严重的肝病状态。

在这项最新研究中,研究团队发现NRG4激素可以抑制NASH小鼠向肝细胞癌的发展,与NRG4技术水平正常的小鼠相比,缺少NRG4激素的小鼠会出现更严重的NASH和更大比例的肝肿瘤。

接下来,研究团队在转基因的NRG4过表达的小鼠模型证实,NRG4激素水平的升高能够抑制NASH发展为肝癌。此外,使用腺相关病毒(AAV)递送NRG4-Fc融合蛋白来治疗NASH相关肝细胞癌小鼠,能够抑制肝细胞癌发展并增加小鼠的存活率。

林建谍教授表示,目前肝癌研究通常集中在癌性肝细胞本身,例如它们如何增殖,以及如何逃避免疫系统杀伤。但这项新研究打破了以肝脏为中心的研究框架,表明了脂肪细胞来源的激素实际上可以重编程肝脏微环境,并对肝癌发展产生重大影响。

林建谍教授

这些研究结果表明,NRG4激素可以作为NASH疾病进展的检查点,而且具有作为治疗靶点的潜力。林建谍团队目前正在研究提高NGR4激素有效性的方法,以更好地了解其对肝脏中T细胞和巨噬细胞的调控作用。

 

原始出处:

Peng Zhang,et al. Neuregulin 4 suppresses NASH-HCC development by restraining tumor-prone liver microenvironment. Cell Metabolism,2022.

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (7)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1897056, encodeId=1a2c189e056ca, content=<a href='/topic/show?id=4a391158248' target=_blank style='color:#2F92EE;'>#MET#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=54, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11582, encryptionId=4a391158248, topicName=MET)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=18fc139, createdName=一闲, createdTime=Mon Jun 26 00:25:59 CST 2023, time=2023-06-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1962821, encodeId=81be1962821e8, content=<a href='/topic/show?id=dbe6445416' target=_blank style='color:#2F92EE;'>#CEL#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=67, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4454, encryptionId=dbe6445416, topicName=CEL)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c3ff68, createdName=维他命, createdTime=Fri Jan 13 15:25:59 CST 2023, time=2023-01-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1872492, encodeId=f01218e2492e9, content=<a href='/topic/show?id=fd764459a8' target=_blank style='color:#2F92EE;'>#Cell#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=46, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4459, encryptionId=fd764459a8, topicName=Cell)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=524d95, createdName=zhaozhouchifen, createdTime=Fri Mar 24 21:25:59 CST 2023, time=2023-03-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1888455, encodeId=22021888455f9, content=<a href='/topic/show?id=d56611584ec' target=_blank style='color:#2F92EE;'>#Meta#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=44, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11584, encryptionId=d56611584ec, topicName=Meta)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d8f4110, createdName=guojianrong, createdTime=Mon Jul 24 03:25:59 CST 2023, time=2023-07-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1400945, encodeId=f17c1400945ec, content=<a href='/topic/show?id=8fde8438079' target=_blank style='color:#2F92EE;'>#脂肪细胞#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=48, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=84380, encryptionId=8fde8438079, topicName=脂肪细胞)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=77712282976, createdName=shenxlcyp, createdTime=Thu Aug 18 10:25:59 CST 2022, time=2022-08-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1577295, encodeId=f72215e7295e0, content=<a href='/topic/show?id=d86d1159e36' target=_blank style='color:#2F92EE;'>#Metabolism#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11597, encryptionId=d86d1159e36, topicName=Metabolism)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=1a6516392333, createdName=1249859em43(暂无昵称), createdTime=Thu Aug 18 10:25:59 CST 2022, time=2022-08-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1598175, encodeId=f94a15981e57a, content=<a href='/topic/show?id=6c6f1e62c5' target=_blank style='color:#2F92EE;'>#ABO#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=1762, encryptionId=6c6f1e62c5, topicName=ABO)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b6c918580135, createdName=闆锋旦, createdTime=Thu Aug 18 10:25:59 CST 2022, time=2022-08-18, status=1, ipAttribution=)]
    2023-06-26 一闲
  2. [GetPortalCommentsPageByObjectIdResponse(id=1897056, encodeId=1a2c189e056ca, content=<a href='/topic/show?id=4a391158248' target=_blank style='color:#2F92EE;'>#MET#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=54, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11582, encryptionId=4a391158248, topicName=MET)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=18fc139, createdName=一闲, createdTime=Mon Jun 26 00:25:59 CST 2023, time=2023-06-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1962821, encodeId=81be1962821e8, content=<a href='/topic/show?id=dbe6445416' target=_blank style='color:#2F92EE;'>#CEL#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=67, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4454, encryptionId=dbe6445416, topicName=CEL)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c3ff68, createdName=维他命, createdTime=Fri Jan 13 15:25:59 CST 2023, time=2023-01-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1872492, encodeId=f01218e2492e9, content=<a href='/topic/show?id=fd764459a8' target=_blank style='color:#2F92EE;'>#Cell#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=46, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4459, encryptionId=fd764459a8, topicName=Cell)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=524d95, createdName=zhaozhouchifen, createdTime=Fri Mar 24 21:25:59 CST 2023, time=2023-03-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1888455, encodeId=22021888455f9, content=<a href='/topic/show?id=d56611584ec' target=_blank style='color:#2F92EE;'>#Meta#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=44, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11584, encryptionId=d56611584ec, topicName=Meta)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d8f4110, createdName=guojianrong, createdTime=Mon Jul 24 03:25:59 CST 2023, time=2023-07-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1400945, encodeId=f17c1400945ec, content=<a href='/topic/show?id=8fde8438079' target=_blank style='color:#2F92EE;'>#脂肪细胞#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=48, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=84380, encryptionId=8fde8438079, topicName=脂肪细胞)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=77712282976, createdName=shenxlcyp, createdTime=Thu Aug 18 10:25:59 CST 2022, time=2022-08-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1577295, encodeId=f72215e7295e0, content=<a href='/topic/show?id=d86d1159e36' target=_blank style='color:#2F92EE;'>#Metabolism#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11597, encryptionId=d86d1159e36, topicName=Metabolism)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=1a6516392333, createdName=1249859em43(暂无昵称), createdTime=Thu Aug 18 10:25:59 CST 2022, time=2022-08-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1598175, encodeId=f94a15981e57a, content=<a href='/topic/show?id=6c6f1e62c5' target=_blank style='color:#2F92EE;'>#ABO#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=1762, encryptionId=6c6f1e62c5, topicName=ABO)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b6c918580135, createdName=闆锋旦, createdTime=Thu Aug 18 10:25:59 CST 2022, time=2022-08-18, status=1, ipAttribution=)]
    2023-01-13 维他命
  3. [GetPortalCommentsPageByObjectIdResponse(id=1897056, encodeId=1a2c189e056ca, content=<a href='/topic/show?id=4a391158248' target=_blank style='color:#2F92EE;'>#MET#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=54, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11582, encryptionId=4a391158248, topicName=MET)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=18fc139, createdName=一闲, createdTime=Mon Jun 26 00:25:59 CST 2023, time=2023-06-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1962821, encodeId=81be1962821e8, content=<a href='/topic/show?id=dbe6445416' target=_blank style='color:#2F92EE;'>#CEL#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=67, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4454, encryptionId=dbe6445416, topicName=CEL)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c3ff68, createdName=维他命, createdTime=Fri Jan 13 15:25:59 CST 2023, time=2023-01-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1872492, encodeId=f01218e2492e9, content=<a href='/topic/show?id=fd764459a8' target=_blank style='color:#2F92EE;'>#Cell#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=46, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4459, encryptionId=fd764459a8, topicName=Cell)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=524d95, createdName=zhaozhouchifen, createdTime=Fri Mar 24 21:25:59 CST 2023, time=2023-03-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1888455, encodeId=22021888455f9, content=<a href='/topic/show?id=d56611584ec' target=_blank style='color:#2F92EE;'>#Meta#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=44, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11584, encryptionId=d56611584ec, topicName=Meta)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d8f4110, createdName=guojianrong, createdTime=Mon Jul 24 03:25:59 CST 2023, time=2023-07-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1400945, encodeId=f17c1400945ec, content=<a href='/topic/show?id=8fde8438079' target=_blank style='color:#2F92EE;'>#脂肪细胞#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=48, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=84380, encryptionId=8fde8438079, topicName=脂肪细胞)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=77712282976, createdName=shenxlcyp, createdTime=Thu Aug 18 10:25:59 CST 2022, time=2022-08-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1577295, encodeId=f72215e7295e0, content=<a href='/topic/show?id=d86d1159e36' target=_blank style='color:#2F92EE;'>#Metabolism#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11597, encryptionId=d86d1159e36, topicName=Metabolism)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=1a6516392333, createdName=1249859em43(暂无昵称), createdTime=Thu Aug 18 10:25:59 CST 2022, time=2022-08-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1598175, encodeId=f94a15981e57a, content=<a href='/topic/show?id=6c6f1e62c5' target=_blank style='color:#2F92EE;'>#ABO#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=1762, encryptionId=6c6f1e62c5, topicName=ABO)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b6c918580135, createdName=闆锋旦, createdTime=Thu Aug 18 10:25:59 CST 2022, time=2022-08-18, status=1, ipAttribution=)]
  4. [GetPortalCommentsPageByObjectIdResponse(id=1897056, encodeId=1a2c189e056ca, content=<a href='/topic/show?id=4a391158248' target=_blank style='color:#2F92EE;'>#MET#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=54, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11582, encryptionId=4a391158248, topicName=MET)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=18fc139, createdName=一闲, createdTime=Mon Jun 26 00:25:59 CST 2023, time=2023-06-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1962821, encodeId=81be1962821e8, content=<a href='/topic/show?id=dbe6445416' target=_blank style='color:#2F92EE;'>#CEL#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=67, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4454, encryptionId=dbe6445416, topicName=CEL)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c3ff68, createdName=维他命, createdTime=Fri Jan 13 15:25:59 CST 2023, time=2023-01-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1872492, encodeId=f01218e2492e9, content=<a href='/topic/show?id=fd764459a8' target=_blank style='color:#2F92EE;'>#Cell#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=46, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4459, encryptionId=fd764459a8, topicName=Cell)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=524d95, createdName=zhaozhouchifen, createdTime=Fri Mar 24 21:25:59 CST 2023, time=2023-03-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1888455, encodeId=22021888455f9, content=<a href='/topic/show?id=d56611584ec' target=_blank style='color:#2F92EE;'>#Meta#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=44, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11584, encryptionId=d56611584ec, topicName=Meta)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d8f4110, createdName=guojianrong, createdTime=Mon Jul 24 03:25:59 CST 2023, time=2023-07-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1400945, encodeId=f17c1400945ec, content=<a href='/topic/show?id=8fde8438079' target=_blank style='color:#2F92EE;'>#脂肪细胞#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=48, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=84380, encryptionId=8fde8438079, topicName=脂肪细胞)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=77712282976, createdName=shenxlcyp, createdTime=Thu Aug 18 10:25:59 CST 2022, time=2022-08-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1577295, encodeId=f72215e7295e0, content=<a href='/topic/show?id=d86d1159e36' target=_blank style='color:#2F92EE;'>#Metabolism#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11597, encryptionId=d86d1159e36, topicName=Metabolism)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=1a6516392333, createdName=1249859em43(暂无昵称), createdTime=Thu Aug 18 10:25:59 CST 2022, time=2022-08-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1598175, encodeId=f94a15981e57a, content=<a href='/topic/show?id=6c6f1e62c5' target=_blank style='color:#2F92EE;'>#ABO#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=1762, encryptionId=6c6f1e62c5, topicName=ABO)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b6c918580135, createdName=闆锋旦, createdTime=Thu Aug 18 10:25:59 CST 2022, time=2022-08-18, status=1, ipAttribution=)]
    2023-07-24 guojianrong
  5. [GetPortalCommentsPageByObjectIdResponse(id=1897056, encodeId=1a2c189e056ca, content=<a href='/topic/show?id=4a391158248' target=_blank style='color:#2F92EE;'>#MET#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=54, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11582, encryptionId=4a391158248, topicName=MET)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=18fc139, createdName=一闲, createdTime=Mon Jun 26 00:25:59 CST 2023, time=2023-06-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1962821, encodeId=81be1962821e8, content=<a href='/topic/show?id=dbe6445416' target=_blank style='color:#2F92EE;'>#CEL#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=67, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4454, encryptionId=dbe6445416, topicName=CEL)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c3ff68, createdName=维他命, createdTime=Fri Jan 13 15:25:59 CST 2023, time=2023-01-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1872492, encodeId=f01218e2492e9, content=<a href='/topic/show?id=fd764459a8' target=_blank style='color:#2F92EE;'>#Cell#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=46, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4459, encryptionId=fd764459a8, topicName=Cell)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=524d95, createdName=zhaozhouchifen, createdTime=Fri Mar 24 21:25:59 CST 2023, time=2023-03-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1888455, encodeId=22021888455f9, content=<a href='/topic/show?id=d56611584ec' target=_blank style='color:#2F92EE;'>#Meta#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=44, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11584, encryptionId=d56611584ec, topicName=Meta)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d8f4110, createdName=guojianrong, createdTime=Mon Jul 24 03:25:59 CST 2023, time=2023-07-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1400945, encodeId=f17c1400945ec, content=<a href='/topic/show?id=8fde8438079' target=_blank style='color:#2F92EE;'>#脂肪细胞#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=48, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=84380, encryptionId=8fde8438079, topicName=脂肪细胞)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=77712282976, createdName=shenxlcyp, createdTime=Thu Aug 18 10:25:59 CST 2022, time=2022-08-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1577295, encodeId=f72215e7295e0, content=<a href='/topic/show?id=d86d1159e36' target=_blank style='color:#2F92EE;'>#Metabolism#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11597, encryptionId=d86d1159e36, topicName=Metabolism)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=1a6516392333, createdName=1249859em43(暂无昵称), createdTime=Thu Aug 18 10:25:59 CST 2022, time=2022-08-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1598175, encodeId=f94a15981e57a, content=<a href='/topic/show?id=6c6f1e62c5' target=_blank style='color:#2F92EE;'>#ABO#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=1762, encryptionId=6c6f1e62c5, topicName=ABO)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b6c918580135, createdName=闆锋旦, createdTime=Thu Aug 18 10:25:59 CST 2022, time=2022-08-18, status=1, ipAttribution=)]
  6. [GetPortalCommentsPageByObjectIdResponse(id=1897056, encodeId=1a2c189e056ca, content=<a href='/topic/show?id=4a391158248' target=_blank style='color:#2F92EE;'>#MET#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=54, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11582, encryptionId=4a391158248, topicName=MET)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=18fc139, createdName=一闲, createdTime=Mon Jun 26 00:25:59 CST 2023, time=2023-06-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1962821, encodeId=81be1962821e8, content=<a href='/topic/show?id=dbe6445416' target=_blank style='color:#2F92EE;'>#CEL#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=67, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4454, encryptionId=dbe6445416, topicName=CEL)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c3ff68, createdName=维他命, createdTime=Fri Jan 13 15:25:59 CST 2023, time=2023-01-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1872492, encodeId=f01218e2492e9, content=<a href='/topic/show?id=fd764459a8' target=_blank style='color:#2F92EE;'>#Cell#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=46, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4459, encryptionId=fd764459a8, topicName=Cell)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=524d95, createdName=zhaozhouchifen, createdTime=Fri Mar 24 21:25:59 CST 2023, time=2023-03-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1888455, encodeId=22021888455f9, content=<a href='/topic/show?id=d56611584ec' target=_blank style='color:#2F92EE;'>#Meta#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=44, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11584, encryptionId=d56611584ec, topicName=Meta)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d8f4110, createdName=guojianrong, createdTime=Mon Jul 24 03:25:59 CST 2023, time=2023-07-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1400945, encodeId=f17c1400945ec, content=<a href='/topic/show?id=8fde8438079' target=_blank style='color:#2F92EE;'>#脂肪细胞#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=48, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=84380, encryptionId=8fde8438079, topicName=脂肪细胞)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=77712282976, createdName=shenxlcyp, createdTime=Thu Aug 18 10:25:59 CST 2022, time=2022-08-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1577295, encodeId=f72215e7295e0, content=<a href='/topic/show?id=d86d1159e36' target=_blank style='color:#2F92EE;'>#Metabolism#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11597, encryptionId=d86d1159e36, topicName=Metabolism)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=1a6516392333, createdName=1249859em43(暂无昵称), createdTime=Thu Aug 18 10:25:59 CST 2022, time=2022-08-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1598175, encodeId=f94a15981e57a, content=<a href='/topic/show?id=6c6f1e62c5' target=_blank style='color:#2F92EE;'>#ABO#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=1762, encryptionId=6c6f1e62c5, topicName=ABO)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b6c918580135, createdName=闆锋旦, createdTime=Thu Aug 18 10:25:59 CST 2022, time=2022-08-18, status=1, ipAttribution=)]
  7. [GetPortalCommentsPageByObjectIdResponse(id=1897056, encodeId=1a2c189e056ca, content=<a href='/topic/show?id=4a391158248' target=_blank style='color:#2F92EE;'>#MET#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=54, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11582, encryptionId=4a391158248, topicName=MET)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=18fc139, createdName=一闲, createdTime=Mon Jun 26 00:25:59 CST 2023, time=2023-06-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1962821, encodeId=81be1962821e8, content=<a href='/topic/show?id=dbe6445416' target=_blank style='color:#2F92EE;'>#CEL#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=67, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4454, encryptionId=dbe6445416, topicName=CEL)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c3ff68, createdName=维他命, createdTime=Fri Jan 13 15:25:59 CST 2023, time=2023-01-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1872492, encodeId=f01218e2492e9, content=<a href='/topic/show?id=fd764459a8' target=_blank style='color:#2F92EE;'>#Cell#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=46, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4459, encryptionId=fd764459a8, topicName=Cell)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=524d95, createdName=zhaozhouchifen, createdTime=Fri Mar 24 21:25:59 CST 2023, time=2023-03-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1888455, encodeId=22021888455f9, content=<a href='/topic/show?id=d56611584ec' target=_blank style='color:#2F92EE;'>#Meta#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=44, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11584, encryptionId=d56611584ec, topicName=Meta)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d8f4110, createdName=guojianrong, createdTime=Mon Jul 24 03:25:59 CST 2023, time=2023-07-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1400945, encodeId=f17c1400945ec, content=<a href='/topic/show?id=8fde8438079' target=_blank style='color:#2F92EE;'>#脂肪细胞#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=48, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=84380, encryptionId=8fde8438079, topicName=脂肪细胞)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=77712282976, createdName=shenxlcyp, createdTime=Thu Aug 18 10:25:59 CST 2022, time=2022-08-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1577295, encodeId=f72215e7295e0, content=<a href='/topic/show?id=d86d1159e36' target=_blank style='color:#2F92EE;'>#Metabolism#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11597, encryptionId=d86d1159e36, topicName=Metabolism)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=1a6516392333, createdName=1249859em43(暂无昵称), createdTime=Thu Aug 18 10:25:59 CST 2022, time=2022-08-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1598175, encodeId=f94a15981e57a, content=<a href='/topic/show?id=6c6f1e62c5' target=_blank style='color:#2F92EE;'>#ABO#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=1762, encryptionId=6c6f1e62c5, topicName=ABO)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b6c918580135, createdName=闆锋旦, createdTime=Thu Aug 18 10:25:59 CST 2022, time=2022-08-18, status=1, ipAttribution=)]
    2022-08-18 闆锋旦

相关资讯

华南首例!暨南大学附属第一医院开展钇90微球精准治疗肝癌

整个介入手术历时一个小时,过程顺利,目前患者生命体征平稳,没有明显不良反应。

European Radiology:如何应用影像学方法预测肝癌局部治疗后的术后复发?

最近,临床上提出了肝脏影像报告和数据系统治疗反应(LR-TR)算法对LRT后的肿瘤进行逐个影像学评估。

European Radiology:基于AI的全自动脾分割在肝癌TACE患者风险分层中的应用

随着人工智能领域的发展,该技术为临床提供了关于自动器官分割和体积评估的可能,可以很容易地实时整合到临床工作流程中。

中国发病和死亡人数占全球一半的这种肿瘤,其实完全可避免

乙肝-肝硬化-肝癌的联系,以及肝癌的预防。

局部控制率最高95.7%!近15年研究证实大分割质子治疗肝癌效果显著!

大分割质子治疗在肝癌治疗领域起到了重要的作用,显著提高了肝癌患者的生存率。

中国肝癌规范诊疗质量控制指标(2022版)

《中国肝癌规范诊疗质量控制指标(2022版)》由国家癌症中心和国家肿瘤质控中心发布